Panacea-Sanofi settle first of its kind patent infringement case
Panacea has agreed to forego its claim for damages and rendition of accounts in the proceedings against Sanofi as prayed in the suit it had filed in the Delhi High Court.
sanofi india 4
September 2024
September 2022
NLEM impact: Sanofi's flagship insulin Lantus to take ₹110 cr hit
Nirmal Bang says it estimates Lantus’ annual sales in India for Sanofi at ₹550 crore and hence the impact due to price reduction on revenue would be ₹110 crore.
